



NASDAQ: TOMZ



Providing industry standard disinfection and decontamination technology through the design, development and global deployment of our state-of-the-art SteraMist product line and services

KEY FINANCIAL STATISTICS

\$7.9M

IN TOTAL ORDERS YTD **DRIVEN BY CES SALES*** 25%

INCREASE IN YTD BOOKINGS YOY*

61.8%

GROSS MARGIN YTD*

*at September 30.2022

INVESTMENT HIGHLIGHTS

CUTTING EDGE TECHNOLOGY

- TOMI BIT is the industry's ONLY low- Life Sciences, Hospitals, healthcare percentage hydrogen peroxide solution capable of delivering six log kill with a dwell time of seconds
- No compromise to human health or adversely affecting medical and lab equipment

EXPANDING MARKET DEMAND

- Additional market verticals including food safety and cannabis
- Market expected to grow at a CAGR of 8.2% from 2022-2030; expected to reach \$18.6 billion by 2030

GLOBAL CUSTOMER BASE

- facilities, bio laboratories, state/local institutions, schools, restoration partners, sports organizations, offices, aerospace partners and more
- Rising demand from Asia, Europe & Middle Fast

REVOLUTIONARY PRODUCT LINE

- The SteraPak is the most mobile SteraMist unit available on the market. placing the innovative SteraMist iHP technology onto the customers back
- Custom Engineered Systems eliminate human error and provide accuracy unmatched by competing solutions

SKILLED MANAGEMENT TEAM

- Visionary CEO Dr. Halden Shane
- Proven success delivering on business. operations and regulatory milestones
- Transformed TOMI's SteraMist Technology to industry standard of disinfection and decontamination technology

SUCCESSFUL BUSINESS MODEL

- Recurring revenue stream from sales of BIT solution
- High margin razor/razor blade model
- Capital efficient business infrastructure

DIVISIONS











UNIQUE NON-CORROSIVE TECHNOLOGY

REGISTRATIONS & INTELLECTUAL PROPERTY


SteraMist BIT

contains no toxic chemicals that are highly corrosive and no harmful silver ions

















CUTTING EDGE IONIZED HYDROGEN PEROXIDE PROCESS

1. COLD PLASMA

2. DISPERSION

3. CONTACT

4. DISRUPTION












7.8% hydrogen peroxide BIT Solution converts to iHP after passing through a cold plasma iHP is carried throughout the mist, moving like a gas throughout the treated area. iHP damages pathogenic organisms through oxidation of proteins, carbohydrates, and lipids.

Cellular disruptions and/or dysfunctions occur and allows for disinfection & decontamination in the targeted area.

MARKET DEMAND

- Global Disinfectant Spray Market expected to grow at a CAGR of 8.2% from \$9.9 billion in 2022 to \$18.6 billion in 2030*
- Demand for effective disinfection products has grown consistently since 2014 as a result of the proliferation of hospital acquired Infections and growing food safety concerns
- TOMI can deliver disinfection/decontamination that Is highly effective (six log kill), fast acting and safe



REPRESENTATIVES & DISTRIBUTORS AROUND THE GLOBE



CONTACT INFO

TOMI ENVIRONMENTAL SOLUTIONS, INC. I STERAMIST 8430 Spires Way Frederick, MD 21701 TOMIMIST.COM

IMS INVESTOR RELATIONS John Nesbett/Jen Belodeau 203-972-9200 tomi@imsinvestorrelations.com

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This fact sheet contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management's judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to customer orders for our CES solutions, the advantages of CES solutions and expected growth of sales opportunities. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues: the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forwardlooking statements. All information provided in this fact sheet is as of today's date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.